Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The vaccine will offer protection against H5N1 and is projected to be effective against future viral mutations.

New bacterial mRNA vaccine technology shows promise in fighting plague, and could help address the global threat of ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory winning streak, which has also included nods for a next-gen COVID-19 vaccine ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...